MarkRWielandMD

Ophthalmology • Mountain View, CA

Retinal Disease

Physician

Join to view full profile

Dr. Wieland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wieland's full profile

Already have an account?

Office
2485 Hospital Dr
Suite 200
Mountain View, CA 94040
Phone+1 650-988-7480

Fax+1 650-988-7482

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Ophthalmology, 1989 - 1990
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1986 - 1989
University of California (San Francisco)Internship, Internal Medicine, 1985 - 1986
Case Western Reserve University School of MedicineClass of 1985

Certifications & Licensure

NY State Medical License 1989 - Present
CA State Medical License 1990 - 2025
PA State Medical License 1987 - 1989
OH State Medical License 1985 - 1986
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Top MD Consumers Checkbook
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation Start of enrollment: 2011 Feb 01
Completed
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. Start of enrollment: 2013 Oct 01
Completed
Phase 1, Phase 2
Intravitreal Gas for Vitreomacular Adhesion Start of enrollment: 2013 Nov 01
Withdrawn
Not Applicable
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Start of enrollment: 2014 Sep 17
Completed
Phase 1, Phase 2
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD Start of enrollment: 2015 Jun 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

20 citations
The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery.
Shrirang V Ranade, Mark R Wieland, Tammy Tam, Jennifer C Rea, Judit Horvath
Drug Delivery. 2022-12-01
8 citations
Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab.
Carl C Awh, Giulio Barteselli, Sneha Makadia, Robert T Chang, Jay M Stewart
Ophthalmology. Retina. 2022-11-01
11 citations
Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Clement K Chan, Maziar Lalezary, Prema Abraham, Michael Elman, Wesley Thomas Beaulieu
Ophthalmology. Retina. 2022-06-01

Press Mentions

SUBSPECIALTY NEWS: Prophylactic Eylea, Combination Therapy for Wet AMD, Plasma Kallikrein Inhibitors, Bionic Eye, and MoreAugust 30th, 2019

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow